A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Clinical trial NCT04980872 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04980872
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

Start date: 2021-11-02
Primary completion: 2030-02-07
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.